QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:ITOS

iTeos Therapeutics - ITOS Stock Forecast, Price & News

$21.12
-1.13 (-5.08%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.11
$22.76
50-Day Range
$17.53
$22.62
52-Week Range
$16.21
$37.88
Volume
324,006 shs
Average Volume
346,378 shs
Market Capitalization
$751.34 million
P/E Ratio
3.07
Dividend Yield
N/A
Price Target
$34.00

iTeos Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
61.0% Upside
$34.00 Price Target
Short Interest
Bearish
5.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of iTeos Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $2.85 to ($3.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

Medical Sector

1011th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

166th out of 170 stocks


ITOS stock logo

About iTeos Therapeutics (NASDAQ:ITOS) Stock

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITOS Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
iTeos Therapeutics: Too Many Unknowns
Is BioNTech (BNTX) a Great Value Stock Right Now?
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITOS Company Calendar

Last Earnings
11/10/2022
Today
1/27/2023
Next Earnings (Estimated)
3/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+61.0%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$214.52 million
Pretax Margin
77.06%

Debt

Sales & Book Value

Annual Sales
$344.77 million
Cash Flow
$5.69 per share
Book Value
$15.67 per share

Miscellaneous

Free Float
33,263,000
Market Cap
$751.34 million
Optionable
Not Optionable
Beta
1.38

Key Executives

  • Dr. Michel Detheux Ph.D. (Age 56)
    Pres, CEO & Director
    Comp: $936.5k
  • Mr. Matthew A. Call M.B.A. (Age 49)
    Chief Operating Officer
    Comp: $626.98k
  • Dr. Joanne  Jenkins-Lager M.D.Dr. Joanne Jenkins-Lager M.D. (Age 50)
    Chief Medical Officer
    Comp: $669.5k
  • Mr. Matthew  GallMr. Matthew Gall (Age 45)
    Chief Financial Officer
  • Dr. Yvonne McGrath Ph.D. (Age 48)
    Chief Scientific Officer
  • Mr. Ryan Baker
    Head of Investor Relations
  • Mr. Phillipe Brantegem
    Vice-Pres of HR













ITOS Stock - Frequently Asked Questions

What is iTeos Therapeutics' stock price forecast for 2023?

0 equities research analysts have issued twelve-month price objectives for iTeos Therapeutics' shares. Their ITOS share price forecasts range from $34.00 to $34.00. On average, they expect the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 54.5% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2023?

iTeos Therapeutics' stock was trading at $19.53 at the beginning of the year. Since then, ITOS shares have increased by 12.7% and is now trading at $22.01.
View the best growth stocks for 2023 here
.

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,460,000 shares, an increase of 5.0% from the December 31st total of 1,390,000 shares. Based on an average trading volume of 328,200 shares, the short-interest ratio is presently 4.4 days. Currently, 5.1% of the company's stock are short sold.
View iTeos Therapeutics' Short Interest
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings results on Thursday, November, 10th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.04. The company earned $19.49 million during the quarter, compared to analyst estimates of $42.05 million. iTeos Therapeutics had a trailing twelve-month return on equity of 42.62% and a net margin of 57.48%.

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is iTeos Therapeutics' stock symbol?

iTeos Therapeutics trades on the NASDAQ under the ticker symbol "ITOS."

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.31%), Strs Ohio (0.08%), Exchange Traded Concepts LLC (0.08%), Yousif Capital Management LLC (0.07%), Ziegler Capital Management LLC (0.06%) and Comerica Bank (0.04%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends
.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iTeos Therapeutics' stock price today?

One share of ITOS stock can currently be purchased for approximately $22.01.

How much money does iTeos Therapeutics make?

iTeos Therapeutics (NASDAQ:ITOS) has a market capitalization of $783.01 million and generates $344.77 million in revenue each year. The company earns $214.52 million in net income (profit) each year or $6.88 on an earnings per share basis.

How can I contact iTeos Therapeutics?

The official website for the company is www.iteostherapeutics.com. The company can be reached via phone at 339-217-0161 or via email at ir@iteostherapeutics.com.

This page (NASDAQ:ITOS) was last updated on 1/27/2023 by MarketBeat.com Staff